Arcturus Therapeutics is trading at $14.21, up 10.41%, with Leerink Partners’ price-target increase potentially supporting the gain. - On October 9, Leerink Partners maintained an Outperform rating and raised its target from $13 to $19. - Biotech-sector strength may also be helping; XBI rose 2.50% during the regular session. - The stock closed at $12.87 on October 8, making today’s move substantially larger than the sector advance.